Quanterix Q2 revenue rises 34% but cuts 2026 outlook

Quanterix

10/08/2026 13:12

Overview
Precision biomarker science firm's Q2 revenue rose 34% yr/yr amid execution challenges and market softness
Adjusted EBITDA loss for Q2 narrowed to $10.0 mln from $13.7 mln in prior yr
Company revised 2026 revenue outlook downward and delayed cash flow breakeven target to 2027

Outlook
Quanterix sees 2026 revenue of $142-148 mln, down from prior $169-174 mln forecast
Company expects 2026 non-GAAP gross margin of 48-50%, down from 49-53% previously
Quanterix now anticipates cash flow breakeven in 2027, not 2026

Result Drivers
EXECUTION CHALLENGES - Co said revenue fell short of expectations due to execution issues and continued market softness
COMMERCIAL REORGANIZATION - Co reorganized teams and added experienced leaders to address performance and accountability
ALZHEIMER'S TESTING MILESTONES - Co reported progress in advancing clinical adoption of blood-based Alzheimer's testing, including new insurance coverage and clinical data

Company press release: ID:nBwbg2BjZa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$23.48 mln
 
Q2 Net Loss
 
$48.93 mln
 
Q2 Gross Profit
 
$12.67 mln
 
Q2 Loss Per Basic Share
 
$1.04
 
Q2 Operating Expenses
 
$62.11 mln
 
Q2 Operating Income
 
-$49.43 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corporation is $4.00, about 0.7% below its August 7 closing price of $4.03

Reuters Recommended Reads
Aug 7 - Doximity set for biggest daily jump ever as investors bet on AI optimism
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates 
Aug 10 - Tenax Therapeutics' heart drug misses main goal in study, shares plunge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)